11:43 AM
 | 
Mar 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eisai, Purdue's lemborexant meets in Phase III for insomnia

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase III SUNRISE 1 trial in about 1,000 patients ages 55 and older with insomnia showing that oral lemborexant (E2006) given each night before bedtime met the primary endpoint...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >